NASDAQ:SUPN

Supernus Pharmaceuticals Competitors

$28.31
+0.20 (+0.71 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.71
Now: $28.31
$28.36
50-Day Range
$24.15
MA: $26.89
$30.94
52-Week Range
$17.20
Now: $28.31
$31.99
Volume374,528 shs
Average Volume602,185 shs
Market Capitalization$1.50 billion
P/E Ratio11.75
Dividend YieldN/A
Beta1.38

Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying SUPN stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Supernus Pharmaceuticals, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Supernus Pharmaceuticals (NASDAQ:SUPN) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Supernus Pharmaceuticals and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$392.76 million3.81$113.06 million$2.1013.48
Johnson & Johnson$82.06 billion5.17$15.12 billion$8.6818.58

Johnson & Johnson has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Supernus Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Supernus Pharmaceuticals27.09%20.02%9.67%
Johnson & Johnson21.01%34.64%13.40%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Supernus Pharmaceuticals and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Supernus Pharmaceuticals02102.33
Johnson & Johnson031102.79

Supernus Pharmaceuticals currently has a consensus price target of $27.6667, indicating a potential downside of 2.27%. Johnson & Johnson has a consensus price target of $180.6429, indicating a potential upside of 12.03%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Supernus Pharmaceuticals.

Insider & Institutional Ownership

96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 6.6% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Supernus Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Profitability

This table compares Pfizer and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
Supernus Pharmaceuticals27.09%20.02%9.67%

Volatility and Risk

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Institutional and Insider Ownership

67.4% of Pfizer shares are held by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Pfizer and Supernus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010302.23
Supernus Pharmaceuticals02102.33

Pfizer presently has a consensus target price of $38.5714, suggesting a potential upside of 5.39%. Supernus Pharmaceuticals has a consensus target price of $27.6667, suggesting a potential downside of 2.27%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Supernus Pharmaceuticals.

Earnings and Valuation

This table compares Pfizer and Supernus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.94$16.27 billion$2.9512.41
Supernus Pharmaceuticals$392.76 million3.81$113.06 million$2.1013.48

Pfizer has higher revenue and earnings than Supernus Pharmaceuticals. Pfizer is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Supernus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Merck & Co., Inc. and Supernus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.12$9.84 billion$5.1914.70
Supernus Pharmaceuticals$392.76 million3.81$113.06 million$2.1013.48

Merck & Co., Inc. has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Merck & Co., Inc. and Supernus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021202.86
Supernus Pharmaceuticals02102.33

Merck & Co., Inc. presently has a consensus price target of $95.9167, suggesting a potential upside of 25.69%. Supernus Pharmaceuticals has a consensus price target of $27.6667, suggesting a potential downside of 2.27%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Supernus Pharmaceuticals.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Supernus Pharmaceuticals27.09%20.02%9.67%

Summary

Merck & Co., Inc. beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Valuation and Earnings

This table compares AbbVie and Supernus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.71$7.88 billion$8.9412.03
Supernus Pharmaceuticals$392.76 million3.81$113.06 million$2.1013.48

AbbVie has higher revenue and earnings than Supernus Pharmaceuticals. AbbVie is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Supernus Pharmaceuticals27.09%20.02%9.67%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for AbbVie and Supernus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121402.76
Supernus Pharmaceuticals02102.33

AbbVie presently has a consensus price target of $115.75, indicating a potential upside of 7.63%. Supernus Pharmaceuticals has a consensus price target of $27.6667, indicating a potential downside of 2.27%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Supernus Pharmaceuticals.

Summary

AbbVie beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Eli Lilly and and Supernus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion7.93$8.32 billion$6.0430.54
Supernus Pharmaceuticals$392.76 million3.81$113.06 million$2.1013.48

Eli Lilly and has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eli Lilly and and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Supernus Pharmaceuticals27.09%20.02%9.67%

Analyst Ratings

This is a breakdown of current recommendations for Eli Lilly and and Supernus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041102.73
Supernus Pharmaceuticals02102.33

Eli Lilly and presently has a consensus target price of $196.40, indicating a potential upside of 6.46%. Supernus Pharmaceuticals has a consensus target price of $27.6667, indicating a potential downside of 2.27%. Given Eli Lilly and's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and is more favorable than Supernus Pharmaceuticals.

Risk & Volatility

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Summary

Eli Lilly and beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Supernus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.35$3.44 billion$4.6913.35
Supernus Pharmaceuticals$392.76 million3.81$113.06 million$2.1013.48

Bristol-Myers Squibb has higher revenue and earnings than Supernus Pharmaceuticals. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Supernus Pharmaceuticals27.09%20.02%9.67%

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bristol-Myers Squibb and Supernus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Supernus Pharmaceuticals02102.33

Bristol-Myers Squibb presently has a consensus target price of $74.6429, suggesting a potential upside of 19.22%. Supernus Pharmaceuticals has a consensus target price of $27.6667, suggesting a potential downside of 2.27%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, equities analysts clearly believe Bristol-Myers Squibb is more favorable than Supernus Pharmaceuticals.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bristol-Myers Squibb beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.


Supernus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.25+1.1%$424.52 billion$82.06 billion25.35
Pfizer logo
PFE
Pfizer
2.3$36.60+1.7%$204.14 billion$51.75 billion23.61Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.31+1.1%$193.09 billion$46.84 billion16.88News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.54+1.3%$189.79 billion$33.27 billion22.74Analyst Report
Eli Lilly and logo
LLY
Eli Lilly and
2.1$184.49+1.0%$176.92 billion$22.32 billion30.15
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.61+1.1%$139.87 billion$26.15 billion-569.13Analyst Upgrade
Zoetis logo
ZTS
Zoetis
2.2$159.85+0.1%$75.93 billion$6.26 billion47.43
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.31+0.9%$25.69 billionN/A0.00Analyst Revision
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.48+0.5%$20.50 billion$1.30 billion24.99Analyst Upgrade
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40+0.3%$9.09 billion$2.16 billion50.91Insider Selling
Perrigo logo
PRGO
Perrigo
2.5$40.53+0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63+3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48Insider Selling
Endo International logo
ENDP
Endo International
1.3$6.20+1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Omeros logo
OMER
Omeros
1.4$18.23+2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$19.27+0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.96+12.7%$373.27 million$16.54 million-3.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.55+2.8%$358.06 million$111.39 million25.36News Coverage
Gap Down
Lannett logo
LCI
Lannett
2.0$4.95+1.6%$204.94 million$545.74 million-6.87Analyst Upgrade
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.36+0.5%$166.75 million$15.96 million-2.64Unusual Options Activity
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.17+4.1%$47.30 million$47.53 million-14.41News Coverage
Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.